Accessibility Menu
Ucb logo

Ucb(OTC) UCBJF

Current Price$290.59
Market Cap$55.32BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+616%
5 Year+191%
1 Year+39%
1 Month+1%
Ucb last closing stock price
MetricPriceDate
Last closeUSD 290.592026-07-24
Ucb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.35%USD 273.252026-07-17
1 month+0.76%USD 288.402026-06-24
3 month+0.34%USD 289.612026-04-24
Year to date-0.4%USD 291.772025-12-31
1 year+39.14%USD 208.852025-07-24
3 year+232.42%USD 87.422023-07-25
5 year+191.41%USD 99.722021-07-19
Since inception+616.45%USD 40.562004-04-20

Ucb Financials at a Glance

Market Cap

$55.32BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€13.89B

Net Income (TTM)

€2.62B

EPS (TTM)

$9.18

P/E Ratio

31.01

Dividend

$1.70

Beta (Volatility)

0.00 (Low)

Price

$290.59

Volume

49

Open

$290.59

Previous Close

$290.59

Daily Range

$290.59 - $290.59

52-Week Range

$207.00 - $345.39

Estimated Earnings Date

Jul 30, 2026

UCBJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ucb

UCB S.A. is a leading biopharmaceutical company focused on developing innovative therapies for neurological and immunological disorders. Established in 1925 and headquartered in Brussels, Belgium, UCB has a diverse portfolio of products and a robust pipeline of investigational medicines.

Products and Services
  • Cimzia for inflammatory TNF-mediated diseases
  • Vimpat, Keppra, and Briviact for epilepsy management
  • Evenity for osteoporosis treatment in postmenopausal women
Growth Outlook
  • Recent quarterly revenue reached €4.25 billion, indicating strong market demand
  • Pipeline includes promising therapies for Alzheimer's and Parkinson's diseases
  • Strategic collaborations with major industry players enhance growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of €13.5 billion, reflecting consistent growth
  • Net income margin of 25.4% in the latest quarter demonstrates operational efficiency
  • Strong cash flow with free cash flow of €1.36 billion in the most recent quarter
UCB S.A. has established itself as a significant player in the biopharmaceutical industry, with a focus on addressing unmet medical needs. The company's diverse product offerings, including treatments for chronic conditions, position it well for sustained growth. The recent financial performance highlights a robust revenue stream and strong profitability, which may attract potential investors. With a solid pipeline of investigational therapies and strategic partnerships, UCB is poised for continued success in the evolving healthcare landscape.
AI Generated • Jun 27, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,117

CEO

Jean-Christophe Tellier, MD

Website

www.ucb.com

Headquarters

Brussels, BU 1070, BE

UCBJF Financials

Key Financial Metrics (TTM)

Gross Margin

74.29%

Operating Margin

25.32%

Net Income Margin

20.13%

Return on Equity

15.16%

Return on Capital

8.89%

Return on Assets

8.58%

Earnings Yield

3.22%

Dividend Yield

0.58%

Payout Ratio

16.94%

Stock Overview

Market Cap

$55.32BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

190.36M

Volume

49

Avg. Volume

561.436

Financials (TTM)

Gross Profit

€10.15B

Operating Income

€3.28B

EBITDA

€4.54B

Operating Cash Flow

€3.48B

Capital Expenditure

-€602.94M

Free Cash Flow

€2.87B

Cash & ST Invst.

€2.47B

Total Debt

€2.24B

Ucb Performance Analysis

Ucb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 5,798,225,305-15.1%
20232023-12-31EUR 5,678,019,147-2.1%
20242024-12-31EUR 6,654,561,53317.2%
20252025-12-31EUR 8,736,321,91631.3%
Ucb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-304.8%
Q42024-12-3120.4%
Q22025-06-303.7%
Q42025-12-3122.0%
Ucb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.25-65.0%
20232023-12-31EUR 1.90-15.7%
20242024-12-31EUR 5.92211.7%
20252025-12-31EUR 9.0652.9%
Ucb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30568.8%
Q42024-12-31312.1%
Q22025-06-30-44.7%
Q42025-12-31133.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

€4.25B

+59.7%

Gross Profit

€3.18B

+92.6%

Gross Margin

74.89%

N/A

Market Cap

$55.32BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.47M

N/A

Employees

10,117

N/A

Net Income

€1.08B

+3283.1%

EBITDA

€1.57B

+190.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€2.47B

+167.5%

Total Debt

€2.24B

-26.1%

Accounts Receivable

€1.79B

+72.4%

Inventory

€1.50B

+45.0%

Long Term Debt

€2.18B

-27.2%

Short Term Debt

€62.00M

+47.6%

Return on Assets

8.58%

N/A

Return on Invested Capital

14.25%

N/A

Free Cash Flow

€1.36B

+337.5%

Operating Cash Flow

€1.52B

+224.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HOCPFHOYA Corporation
$154.17+0.00%
IPSEYIpsen S.A.
$44.81-4.88%
LZAGYLonza Group AG
$67.09+1.25%
LZAGFLonza Group AG
$675.41+1.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
AALAmerican Airlines Group
$14.48+0.07%

Questions About UCBJF

What is the current price of Ucb?

Ucb is trading at $290.59 per share.

What is the 52-week range for Ucb?

Over the past 52 weeks, Ucb has traded between $207.00 and $345.39.

How much debt does Ucb have?

As of the most recent reporting period, Ucb reported total debt of €2.64B.

How much cash does Ucb have on hand?

Ucb reported €2.64B in cash and cash equivalents in its most recent financial results.

What is Ucb’s dividend yield?

Ucb currently has a dividend yield of 0.58%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services